Does p-glycoprotein play a role in anticancer drug pharmacokinetics?

Drug Resistance Updates

Volumn 3, Issue 6, 2000, Pages 357-363

  Sparreboom, Alex ^a   Nooter, Kees ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOSPORIN A; CYTOCHROME P450 3A4; DOCETAXEL; DOXORUBICIN; DRUG METABOLIZING ENZYME; ELACRIDAR; ETOPOSIDE; GLYCOPROTEIN P; PACLITAXEL; VALSPODAR; VERAPAMIL; ZOSUQUIDAR;

BINDING AFFINITY; CANCER CHEMOTHERAPY; COMPETITIVE INHIBITION; DRUG CLEARANCE; DRUG EFFICACY; DRUG POTENCY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW;

EID: 0034496578     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2000.0164     Document Type: Article

References (59)

1. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
2. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
3. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines
4. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells
5. Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone selected cell lines
6. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
7. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
8. Absence of pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure
9. Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage
10. Choroid plexus epithelial expression of MDR1 P-glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier
11. Multidrug resistance (MDR1) P-glycoprotein enhances esterification of plasma membrane cholesterol
12. A physiologic function for P-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels
13. Development of multidrug-resistance convertors: Sense or nonsense?
14. Multidrug resistance in haematological malignancies
15. Clinical trials of agents that reverse multidrug resistance
16. Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs?
17. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel
18. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans
19. A phase I and pharmacokinetic study of docetaxel and LY335979 in patients with advanced malignancies
20. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein
21. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance
22. Mechanisms of action of cancer chemotherapeutics: Antitumor antibiotics
23. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein
24. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient mice
25. The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice
26. Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1α P-glycoprotein
27. Preclinical pharmacokinetics of paclitaxel and docetaxel: A review
28. Modulation of doxorubicin concentrations by cyclosporin A in brain and testicular tissues expressing P-glycoprotein in rats
29. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropylbenzosuberane modulator. LY335979
30. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance
31. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer
32. Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice
33. Phase I trial of cremophor EL with bolus doxorubicin
34. Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80
35. Phase I study of mitoxantrone plus etoposide with mutlidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia
36. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer
37. Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia
38. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
39. Identification of P450 enzymes involved in metabolism of verapamil in humans
40. Cyclosporine metabolism in human liver: Identification of a cytochrome P-450111 gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs
41. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A; implications for drug-drug interactions and pharmacological activity of the main metabolite
42. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
43. O-Demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4
44. Detoxification of vinca alkaloids by human P450 CYP3A4-mediated metabolism: Implications for the development of drug resistance
45. Modulation of vinblastine resistance with cyclosporin: A phase I study
46. A dose finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors
47. In vivo antitumor activity and host toxicity of methylmorpholinyl doxorubicin: Role of cytochrome P450 3A
48. Effects of dexamethasone on the pharmacokinetics of adriamycin after intravenous administration to rats
49. Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and unknown P450 enzyme
50. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A
51. 3H]paclitaxel and Cremophor EL in a patient with severely impaired renal function
52. Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (valspodar), in refractory malignancies
53. Valspodar (V) + paclitaxel (P) in advanced breast cancer: A California Cancer Consortium phase II randomized trial
54. P-glycoprotein and cytochrome P-450 3A inhibition: Dissociation of inhibitory potencies
55. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities
56. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance
57. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP
58. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications
59. Future perspectives for the development of P-glycoprotein modulators